The UK is ramping up efforts to become a global first choice for clinical trials, as new figures published today (13 January), show a sharp rise in activity in 2025, and changes coming this year – including a fast-track route – that will help companies get studies up and running more quickly, so patients can benefit from new treatments sooner.
Data from the Medicines and Healthcare products Regulatory Agency (MHRA) shows clinical trial applications received rose by 9 per cent between January and November 2025 compared with the same period in 2024, News Cover reports, citing the UK government.
Growth was strongest in early and innovative research, where speed and expert regulatory support can make or break decisions on where companies invest.
For example, trials involving healthy volunteers – often the first step in testing whether a new medicine is safe – increased by 16 per cent, alongside rises in trials testing treatments in people for the first time (5 per cent), and those being run in the UK for the first time (7 per cent), a sign of growing international confidence in the UK as a place to launch new research.
Companies are also coming to regulators earlier for help. The number of MHRA scientific advice meetings provided on clinical trials rose by 75 per cent over that period, as developers seek to design trials right first time and avoid costly delays later on.
These impressive gains have been made within the limitations of the current regulatory framework. A package of significant changes will be delivered with new clinical trial regulations due to take effect from April. Under the new rules, around one in five studies are expected to move onto a fast-track notification route, which will allow lower-risk trials to start sooner, while maintaining high safety standards and freeing up experts to focus on complex and early-phase studies. The MHRA will also introduce a 14-day assessment route for phase 1 trials, adopting an innovative stepwise approach, restoring a rapid pathway for the earliest testing of new medicines in people – a key draw for global developers deciding where to base their research.
Alongside faster assessments, the new framework will support clearer, more agile routes to support innovation. This includes making better use of early safety data from overseas studies that meet UK standards, and new MHRA capability to assess computer model simulations, such as in-silico trials, to help predict how new medicines may behave before they are tested in patients. The aim is to reflect how modern medicines are developed today, without lowering safety standards.
